Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Organogenesis Holdings Inc.NASDAQ: ORGO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $21.13M, compared with -$19.94M a year earlier. Trailing-twelve-month operating cash flow was $30.75M.
Context
- Operating cash flow amounted to 1.8% of revenue in FY2025, down 1.1 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near $21.13M or moves back toward the trailing-twelve-month quarterly average of $7.69M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10.31M) USD
- Year-over-year change
- -172.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.31M) | -172.6% |
| FY2024 | 2024-12-31 | 14.21M | -54.0% |
| FY2023 | 2023-12-31 | 30.92M | +24.4% |
| FY2022 | 2022-12-31 | 24.86M | -59.9% |
| FY2021 | 2021-12-31 | 61.98M | — |
Operating Cash Flow vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +593.4% is the highest of 11, against a peer median of +16.3%.
- Operating cash flow amounts to 6.0% of revenue for ORGO, versus a peer median of 9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.9M USD | +26.8% | +42.6% | 360.5% | |
| LTM Mar 2026 | $148M USD | +34.4% | — | 21.9% | |
| LTM Mar 2026 | CA$66.61M CAD | +12.1% | — | 7.1% | |
| LTM Mar 2026 | $53.2M USD | +20.4% | +12.9% | — | |
| LTM Mar 2026 | $36.59M USD | +59.0% | -20.7% | 12.1% | |
| LTM Mar 2026 | $30.75M USD | +593.4% | — | 6.0% | |
| LTM Mar 2026 | $27.75M USD | -55.2% | +1.5% | 29.6% | |
| LTM Mar 2026 | $18.19M USD | -81.8% | -57.8% | 4.3% | |
| LTM Mar 2026 | $10.01M USD | -3.8% | +19.1% | — | |
| LTM Feb 2026 | $4.45M USD | +118.6% | +12.1% | 1.4% | |
| LTM Apr 2026 | $2M USD | -103.3% | +35.1% | 0.2% | |
| Peer median (excluding ORGO) | — | +16.3% | +12.5% | 9.6% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.